This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

ChemoCentryx Crecimiento futuro

Future controles de criterios 5/6

Información clave

69.1%

Tasa de crecimiento de los beneficios

91.9%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	31.4%
Tasa de crecimiento de los ingresos	85.1%
Rentabilidad financiera futura	6.6%
Cobertura de analistas	Low
Última actualización	n/a

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Previsiones de crecimiento de beneficios e ingresos

DB:2CX - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2024	419	68	-6	116	1
12/31/2023	190	-55	-25	-12	2
12/31/2022	64	-140	-94	-52	2
6/30/2022	37	-133	-59	-53	N/A
3/31/2022	27	-141	-54	-45	N/A
12/31/2021	32	-132	-95	-76	N/A
9/30/2021	34	-121	-112	-84	N/A
6/30/2021	22	-123	-102	-75	N/A
3/31/2021	69	-63	-101	-75	N/A
12/31/2020	65	-55	-97	-81	N/A
9/30/2020	71	-41	-89	-82	N/A
6/30/2020	76	-30	-85	-83	N/A
3/31/2020	34	-65	-81	-79	N/A
12/31/2019	36	-55	-71	-70	N/A
9/30/2019	35	-51	-66	-65	N/A
6/30/2019	34	-49	-66	-66	N/A
3/31/2019	42	-40	-44	-43	N/A
12/31/2018	43	-38	16	16	N/A
9/30/2018	90	12	36	38	N/A
6/30/2018	90	17	41	42	N/A
3/31/2018	84	14	19	20	N/A
12/31/2017	82	18	4	5	N/A
9/30/2017	31	-29	-10	-10	N/A
6/30/2017	26	-30	-5	-5	N/A
3/31/2017	20	-31	76	76	N/A
12/31/2016	12	-40	39	39	N/A
9/30/2016	7	-44	38	39	N/A
6/30/2016	3	-48	38	38	N/A
3/31/2016	N/A	-51	N/A	-41	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: 2CX is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (0.03%).

Beneficios vs. Mercado: 2CX is forecast to become profitable over the next 3 years, which is considered above average market growth.

Beneficios de alto crecimiento: 2CX is expected to become profitable in the next 3 years.

Ingresos vs. Mercado: 2CX's revenue (85.1% per year) is forecast to grow faster than the German market (3.9% per year).

Ingresos de alto crecimiento: 2CX's revenue (85.1% per year) is forecast to grow faster than 20% per year.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: 2CX's Return on Equity is forecast to be low in 3 years time (6.6%).

This company listing is no longer active

ChemoCentryx Crecimiento futuro

Future controles de criterios 5/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Forecast to breakeven in 2024

Recent updates

Amgen Inc. (NasdaqGS:AMGN) completed the acquisition of ChemoCentryx, Inc. (NasdaqGS:CCXI) from a group of shareholders.

Chemocentryx, Inc. Announces Executive Changes

Second quarter 2022 earnings released: US$0.44 loss per share (vs US$0.56 loss in 2Q 2021)

Amgen Inc. (NasdaqGS:AMGN) entered into a definitive agreement to acquire ChemoCentryx, Inc. (NasdaqGS:CCXI) for $3.7 billion.

ChemoCentryx, Inc. to Report Q2, 2022 Results on Aug 09, 2022

Chemocentryx, Inc. Announces Appointment of Jennifer L. Herron to Board as Independent Director

ChemoCentryx, Inc. Appoints Yi Ching Yau as Senior Vice President, Finance and Principal Accounting Officer

Chemocentryx Inc. Reports Safety Results Available from Ongoing Phase I Trial of Orally Administered Pd-L1 Inhibitor, Ccx559, At the 2022 American Society of Clinical Oncology (Asco) Annual Meeting

ChemoCentryx Announces Changes to its Board of Directors

First quarter 2022 earnings released: US$0.55 loss per share (vs US$0.43 loss in 1Q 2021)

Insufficient new directors

ChemoCentryx, Inc. Reports Pharmacokinetic and Pharmacodynamic Results from Ongoing Phase I Trial of Orally Administered PD-L1 Inhibitor, Ccx559, At American Association for Cancer Research (Aacr) Annual Meeting 2022

ChemoCentryx, Inc., Annual General Meeting, May 26, 2022

Insufficient new directors

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

ChemoCentryx, Inc. to Report Q4, 2021 Results on Mar 01, 2022

ChemoCentryx, Inc Announces EU Approval of Tavneos® (Avacopan) for the Treatment of ANCA-Associated Vasculitis

Forecast to breakeven in 2024

Third quarter 2021 earnings released: US$0.32 loss per share (vs US$0.35 loss in 3Q 2020)

ChemoCentryx Announces Approval in Japan of TAVNEOS™ (Avacopan) for the Treatment of ANCA-Associated Vasculitis

Second quarter 2021 earnings released: US$0.56 loss per share (vs US$0.32 profit in 2Q 2020)

Rosen Law Firm Encourages ChemoCentryx, Inc. Investors with Losses to Secure Counsel Before Important July 6, 2021 Deadline in Securities Class Action

Kessler Topaz Meltzer & Check, LLP Announces Securities Fraud Class Action Lawsuit Filed against ChemoCentryx, Inc

Executive VP & COO recently bought €99k worth of stock

ChemoCentryx Announces Results of U.S. Food and Drug Administration Advisory Committee Meeting on Avacopan in ANCA-Associated Vasculitis

Kessler Topaz Meltzer & Check, LLP Announces a Securities Fraud Class Action Filed Against ChemoCentryx, Inc

First quarter 2021 earnings released: US$0.43 loss per share (vs US$0.35 loss in 1Q 2020)

Director recently sold €1.5m worth of stock

ChemoCentryx, Inc Appoint Susan M. Kanaya to the Board of Directors

ChemoCentryx, Inc. Appoints Tausif Butt as Executive Vice President and Chief Operating Officer

Full year 2020 earnings released: US$0.84 loss per share (vs US$0.97 loss in FY 2019)

Revenue misses expectations

Chemocentryx Appoints Tausif (‘Tosh’) Butt as Executive Vice President and Chief Operating Officer

ChemoCentryx, Inc. to Report Q4, 2020 Results on Mar 01, 2021

ChemoCentryx Announces Publication in the New England Journal of Medicine of Results of the Pivotal Phase III Advocate Trial of Avacopan for the Treatment of Anca-Associated Vasculitis

New 90-day high: €54.18

Independent Director recently sold €1.0m worth of stock

Independent Director recently sold €1.3m worth of stock

ChemoCentryx, Inc. and Vifor Fresenius Medical Care Renal Pharma Provide Topline Results from ACCOLADE Trial of Avacopan in C3 Glomerulopathy Including Improved Estimated Glomerular Filtration Rate

New 90-day high: €49.12

New 90-day high: €47.85

New 90-day high: €47.06

Third quarter 2020 earnings released: US$0.35 loss per share

Revenue misses expectations

ChemoCentryx, Inc. to Report Q3, 2020 Results on Nov 09, 2020

ChemoCentryx, Inc. Announces Positive Topline Results of Phase II Aurora Clinical Trial of Avacopan in the Treatment of Hidradenitis Suppurativa (HS)

ChemoCentryx, Inc. Announces FDA Acceptance of the Avacopan New Drug Application for the Treatment of ANCA-Associated Vasculitis

New 90-day low - €42.71

First half earnings released

ChemoCentryx, Inc. to Report Q2, 2020 Results on Aug 10, 2020

ChemoCentryx, Inc.(NasdaqGS:CCXI) dropped from Russell Microcap Index

Previsiones de crecimiento de beneficios e ingresos

Previsiones de crecimiento futuro de los analistas

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

Descubre empresas en crecimiento